Gemcitabine, Cisplatin, and Hyperfractionated Accelerated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Zwitter, Matjaž; Kovač, Viljem; Smrdel, Uroš; Strojan, Primož

doi:10.1016/s1556-0864(15)30378-6

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17][18][19][20][21][22][23][24][25] In fact, gemcitabine is known to be a very potent radiosensitizer even at doses of 50 mg/m 2 . 26 However, toxicities can be severe, and extreme caution is justified when using these agents together. Gemcitabine 300 mg/m 2 plus paclitaxel 30 mg/m 2 combined with radiotherapy turned out to be too toxic in an NSCLC RTOG study using these doses (the "Ping-Pong" trial, i.e., carboplatin/gemcitabine or paclitaxel/gemcitabine) (H. Choy, principal investigator, University of Texas, Southwestern Medical Center, personal communication), and the use of the paclitaxel and gemcitabine combination had to be prematurely terminated.…”

mentioning

confidence: 99%

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer

Hirsh

Soulières

Duclos

et al. 2007

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer

Hirsh

Soulières

Duclos

et al. 2007

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…5 Chemotherapy, whether neoadjuvant or concurrent was shown by other effective in terms of improving tumour control with manageable normal tissue toxicity, thus increasing therapeutic ratio. [6][7][8] However, randomised clinical trials are still needed to validate the efficacy of various chemotherapeutic agents on advanced NSCLC.…”

Section: Journal Of Radiotherapy In Practicementioning

confidence: 99%

Accelerated hypofractionated radiotherapy for advanced lung cancer

et al. 2017

View full text Add to dashboard Cite

Introduction – purposeThe aim of this study is to review the results of applying a hypofractionated radiotherapy schedule for locally advanced inoperable lung cancer in patients who have received chemotherapy. Lung cancer and especially non-small-cell lung cancer is prone to accelerated repopulation and shorter treatment schedules in the form of accelerated radiotherapy have been shown to improve treatment outcome.Patients – methodIn total, 29 patients with inoperable lung cancer (stage II, IIIa,b, IV) were treated with accelerated hypofractionated 3D conformal radiotherapy. All patients received a dose of 55 Gy in 20 fractions (daily dose of 2·75 Gy). The median age was 65·5 years, 87% of patients had stage III–IV disease, 93% of patients received sequential chemotherapy with their radiotherapy. Median follow-up of patients was 36 months.ResultsThe median overall survival from time of diagnosis was 16·5 months and the 1 year overall survival was 31%. Complications were present in 44·8% of the patients and the most common complication (20·7%) was pneumonitis alone. The complication rate was not significantly different according to histological type, stage, type of chemotherapy, presence of recurrence or death.ConclusionAlthough our study limitation is the small number of patients, these data suggest that the efficacy of this hypofractionated schedule could be considered as alternative option to the conventional regimen of 66 Gy given in 33 fractions.

show abstract

“…None of the clinical studies and retrospective observations have shown convincing benefits, so research in this area continues. The overall survival, relapse-free survival, as well as the number of side effects of each treatment method are compared and the degree of reliability for each indicator is established [4][5][6][7][8][9][10][11][12][13][14][15][16][17]. There are data from various randomized studies on increasing the effectiveness of treatment when using NCRT at a dosage of 60-74…”

Section: Introductionmentioning

confidence: 99%

Life Expectancy in Patients With Stage Iii a Non-Small Cell Lung Cancer (Nsclc) Treated With Neoadjuvant Chemoradiotherapy (Ncrt), Neoadjuvant Chemotherapy (Nct), Neoadjuvant Chemotherapy + Adjuvant Radiation Therapy (Nct + Adjuvant Rt)

Maliarchuk¹,

Ganul²,

Borisyuk³

et al. 2022

hpc

View full text Add to dashboard Cite

Background. This work is а comparative study of survival in patients with stage III A non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT) and neoadjuvant chemotherapy and adjuvant radiation therapy (NCT + adjuvant RT). Material and methods. Three groups of 65 people were selected. The first group received NCT, the second group -NCT, and the third group -NCT + adjuvant radiation therapy. The NCRT group received radiation therapy of 30 Gy. Survival was assessed using the Kaplan and Mayer scale and according to the log rank criteria.Results. The statistical criterion for NCRT in relation to NCT was -3.51279, r=0.00044. The statistical criterion for NCRT in relation to NCT + adjuvant RT was -2.88568, r=0.00391. Less reliable dependence was observed between NCT and NCT + adjuvant RT (the statistical criterion =1.809508, p=0.070307). Conclusions. Performing NCT, NCRT or NCT + RT and the status of complete morphological response (CMR) during the revision of histological material, it is possible to predict survival for a period of up to 36 months. NCRT is the optimal method of treatment.

show abstract

Gemcitabine, Cisplatin, and Hyperfractionated Accelerated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer

Cited by 6 publications

References 31 publications

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer

Accelerated hypofractionated radiotherapy for advanced lung cancer

Life Expectancy in Patients With Stage Iii a Non-Small Cell Lung Cancer (Nsclc) Treated With Neoadjuvant Chemoradiotherapy (Ncrt), Neoadjuvant Chemotherapy (Nct), Neoadjuvant Chemotherapy + Adjuvant Radiation Therapy (Nct + Adjuvant Rt)

Contact Info

Product

Resources

About